| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2008.11.034 |
| P698 | PubMed publication ID | 19061928 |
| P50 | author | Peter G. Smith | Q47708456 |
| P2093 | author name string | Vasee S Moorthy | |
| Zarifah Reed | |||
| WHO Malaria Vaccine Advisory Committee | |||
| P2860 | cites work | A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults | Q24804936 |
| A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya | Q28469062 | ||
| A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children | Q28471975 | ||
| From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control | Q30483321 | ||
| Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial | Q34359432 | ||
| A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso | Q36926693 | ||
| Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial | Q38410749 | ||
| Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research | Q43890930 | ||
| Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial | Q46623264 | ||
| A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults | Q47835936 | ||
| Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation | Q47836020 | ||
| Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria | Q47876862 | ||
| A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea | Q47901914 | ||
| Assessment of the Protective Efficacy of Vaccines against Common Diseases Using Case-Control and Cohort Studies | Q56983373 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| vaccine | Q134808 | ||
| public health | Q189603 | ||
| data sharing | Q5227350 | ||
| malaria vaccine | Q6741353 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 624-628 | |
| P577 | publication date | 2008-12-04 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives | |
| P478 | volume | 27 |
| Q21034112 | A review of malaria vaccine clinical projects based on the WHO rainbow table |
| Q34048233 | A simple approach to the estimation of incidence rate difference |
| Q47901082 | A vaccine against malaria: a substantial step forward |
| Q36343077 | Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design |
| Q60924082 | An Evaluation of Active Case Detection in Malaria Control Program in Kiyuni Parish of Kyankwanzi District, Uganda |
| Q37256085 | Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay |
| Q37107195 | Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review |
| Q38961574 | Considerations for Comprehensive Analyses of Sporozoite-Based Controlled Human Malaria Infection Studies |
| Q33778747 | Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya |
| Q30739154 | Estimation of intervention effects using recurrent event time data in the presence of event dependence and a cured fraction |
| Q96343626 | Estimation of the primary, secondary and composite effects of malaria vaccines using data on multiple clinical malaria episodes |
| Q37352530 | Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection |
| Q39954682 | Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials |
| Q34386553 | Implementing new health interventions in developing countries: why do we lose a decade or more? |
| Q44151834 | MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal |
| Q37514406 | Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods |
| Q28484898 | Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso |
| Q34340186 | Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities |
| Q33611463 | Malaria vaccine research and development: the role of the WHO MALVAC committee |
| Q47993536 | Malaria vaccine results face scrutiny |
| Q33969129 | Prospects for malaria elimination in non-Amazonian regions of Latin America |
| Q37698761 | Reducing empiricism in malaria vaccine design |
| Q89991820 | Statistical inference in matched case-control studies of recurrent events |
| Q35198729 | Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children |
| Q36100736 | Template protocol for clinical trials investigating vaccines--focus on safety elements |
| Q28084325 | The March Toward Malaria Vaccines |
| Q28285472 | The RTS,S malaria vaccine |
| Q38577638 | The march toward malaria vaccines |
| Q38059750 | Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine. |
| Q28742277 | Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children |
Search more.